We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
- Authors
Rosenheck, Robert A; Leslie, Douglas L; Sindelar, Jody L; Miller, Edward A; Tariot, Peter N; Dagerman, Karen S; Davis, Sonia M; Lebowitz, Barry D; Rabins, Peter; Hsiao, John K; Lieberman, Jeffery A; Schneider, Lon S; Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators
- Abstract
Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD).
- Publication
Archives of general psychiatry, 2007, Vol 64, Issue 11, p1259
- ISSN
1538-3636
- Publication type
Journal Article
- DOI
10.1001/archpsyc.64.11.1259